Owkin and ADC Therapeutics to build AI models to improve hematologic cancer treatment

Artificial intelligence (AI) startup Owkin is working with biotech company ADC Therapeutics to develop AI models to improve the treatment of hematologic cancers. The partnership will focus on using machine learning to identify biomarkers that could predict patient outcomes.

ADC Therapeutics works to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The collaboration will enable researchers at ADC Therapeutics to develop targeted therapies that offer patients maximum benefit.

David Cahané, Chief Solutions Officer at Owkin, said:

Owkin’s mission is to discover and develop better treatments for patients, starting with the fight against cancer.

Blood cancers affect hundreds of thousands of people globally every year. We are pleased to be working with ADC Therapeutics to harness the power of AI to improve the treatment of hematologic cancer patients and to help accelerate the development of novel medicines.

‍

Patrick van Berkel, PhD, Senior Vice President, Research & Development at ADC Therapeutics, said:

“We are excited to begin this collaboration so that we can maximize treatment outcomes with our targeted ADCs. We want to ensure our therapies provide the greatest benefit to patients with unmet medical needs.”

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.